| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE45573 | SUNOVION PHARMS INC | Process for producing imide compound |
Jun, 2025
(1 year, 8 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9174975 | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Feb, 2024
(4 months from now) | |
| US9815827 | SUNOVION PHARMS INC | Agent for treatment of schizophrenia |
Feb, 2024
(4 months from now) | |
|
US9174975 (Pediatric) | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Aug, 2024
(10 months from now) | |
|
USRE45573 (Pediatric) | SUNOVION PHARMS INC | Process for producing imide compound |
Dec, 2025
(2 years from now) | |
| US8883794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| US9555027 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| US9907794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| US8729085 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
|
US9907794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(3 years from now) | |
|
US8883794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(3 years from now) | |
|
US8729085 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(3 years from now) | |
| US9827242 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(7 years from now) | |
| US9259423 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(7 years from now) | |
|
US9259423 (Pediatric) | SUNOVION PHARMS INC | Method of treatment for mental disorders |
Nov, 2031
(8 years from now) | |
Latuda is owned by Sunovion Pharms Inc.
Latuda contains Lurasidone Hydrochloride.
Latuda has a total of 15 drug patents out of which 0 drug patents have expired.
Latuda was authorised for market use on 28 October, 2010.
Latuda is available in tablet;oral dosage forms.
Latuda can be used as treatment of major depressive episodes associated with bipolar i disorder; treatment of schizophrenia, treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia, treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and/or bipolar disorder, treatment of schizophrenia with improvement in attention function in schizophrenia; treatment of bipolar depression with improvement in attention function in bipolar disorder, treatment of schizophrenia.
The generics of Latuda are possible to be released after 23 November, 2031.
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 October, 2010
Treatment: Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of major depressive episodes associated with bipolar i disorder; Treatment of ...
Dosage: TABLET;ORAL
LATUDA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic